Concord Biotech IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Last Updated Date: Aug 08, 2023Concord Biotech is a leading biotechnology company known for its innovative biopharmaceutical products. The company’s IPO offers investors a chance to join its growth narrative in the pharmaceutical sector.
With a robust portfolio of high-quality products and a positive market sentiment, the Concord Biotech IPO presents a promising investment opportunity in India’s healthcare market. However, investors must evaluate risks and exercise caution before making their decisions.
| Face Value | Rs 1 |
| Price Band | Rs 705 to Rs 741 |
| Listing At | BSE, NSE |
| Min. Order Quantity | 20 Shares |
| Listing Date | 18 August 2023 |
| Offer for Sale | Rs 1,551.00 Crore |
| Fresh Issue | Rs NA Crore |
| IPO Size | Rs 1,551.00 Crore |
| Tick Size | 1 |
Concord Biotech IPO Overview
Concord Biotech is a leading biotechnology company with a focus on the research, development, and manufacturing of biopharmaceutical products. The company has a strong track record of innovation and has built a robust portfolio of high-quality products catering to various therapeutic areas.
The Concord Biotech IPO is a Book Built Issue, allowing investors to bid for shares within the price range of Rs 705 to Rs 741 per share. The IPO consists of 20,925,652 shares, with a total issue size of Rs 1,551.00 Crores.
The IPO includes an Offer for Sale of 20,925,652 shares, providing an opportunity for existing shareholders to divest their stakes.
Upon successful subscription and allotment, the shares of Concord Biotech will be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Investors can trade these shares on the respective exchanges once they are listed.
Concord Biotech’s initial public offering (IPO) provides a chance for investors to join in a notable biotechnology company’s development narrative and perhaps benefit from its prospects in the pharmaceutical business.
Before making an investment choice, investors must thoroughly evaluate the company’s fundamentals and risk considerations, just as they would with any other.
Concord Biotech IPO Important Dates
| Events | Date |
| IPO Opening Date | 4 August 2023 |
| IPO Closing Date | 8 August 2023 |
| Basis of Allotment Finalization | 11 August 2023 |
| Refunds Initiation | 14 August 2023 |
| Credit of Shares to Demat Account | 17 August 2023 |
| Share Listing Date | 18 August 2023 |
Concord Biotech IPO important dates are already released. Concord Biotech’s initial public offering (IPO) is set to begin on August 4, 2023, and end on August 8, 2023.
On Friday, August 4, 2023, the IPO process will begin, allowing investors to begin putting bids for Concord Biotech shares. Investors will be able to subscribe to the IPO until the closing date of Tuesday, August 8, 2023.
Investors who use the Unified Payments Interface (UPI) must confirm their UPI requirements by 5 p.m. on August 8, 2023.
The basis of allocation will be established on Friday, August 11, 2023, following the close of the subscription period, and the shares will be credited to successful applicants’ Demat accounts on Thursday, August 17, 2023.
Concord Biotech IPO Price, Size, Share Offerings
| Face Value | Rs.1 |
| Price Band | Rs 705 to Rs 741 |
| Offer for Sale | Rs 1,551.00 Crore |
| Fresh Issue | Rs NA Crore |
| IPO Size | Rs 1,551.00 Crore |
The Concord Biotech IPO price range has been established at 705 to 741 per share, with a total issue size of 20,925,652 shares worth up to 1,551.00 crores.
The IPO will be listed on the BSE and the NSE. The face value of each share is one, and the lot size is set at twenty shares. Within this lot size, investors can bid on shares.
In addition, the business is offering an attractive employee discount of Rs 70 per share to qualifying workers who participate in the IPO. When the IPO goes live, ordinary investors can apply for a minimum of one lot, or 20 shares, for a fee of $14,820.
For individual investors, the maximum lot size is 13 lots, which is equivalent to 260 shares, with a maximum investment of 192,660.
The lowest Concord Biotech IPO size for Super High Net Worth Individuals (S-HNI) is 14 lots (280 shares), totalling 207,480, and the maximum lot size is 67 lots (1,340 shares), totalling 992,940.
Big High Net Worth Individuals (B-HNI) may apply for a minimum of 68 lots (1,360 shares), for a total of $1,007,760. The Concord Biotech IPO allows investors to actively participate in the biotechnology sector’s development narrative and capitalize on the potential of the company’s unique offers.
Concord Biotech IPO Grey Market Premium
| Date | GMP (Rs.) | Kostak Rate (Rs.) | Subject to Sauda (Rs.) |
| Not Disclosed | |||
The Concord Biotech IPO has generated significant interest in the grey market, with a Grey Market Premium (GMP) of Rs 202. The Concord Biotech IPO GMP is the difference between the grey market price and the IPO price.
In this case, the GMP of Rs 202 indicates that investors are willing to pay Rs 202 more than the IPO price of Rs 741 per share in the unofficial market. With a GMP of Rs 202, the estimated listing price is expected to be around Rs 943 per share, representing a premium of approximately 27.26% over the IPO price.
The subscription levels for the IPO have been impressive, with an oversubscription of 3400 times the minimum lot size of 20 shares, and 47600 times the maximum lot size of 260 shares.
This overwhelming response from investors is a testament to the confidence in Concord Biotech’s prospects and the potential for growth in the biotechnology sector.
The IPO has received a positive rating of 4/5, indicating a strong belief in the company’s fundamentals and future potential. The total issue size for the Concord Biotech IPO is Rs 1,551.00 Crores.
As of August 1, 2023, at 05:30 PM, the Grey Market Premium (GMP) for the Concord Biotech IPO has been updated to Rs 202. This dynamic GMP indicates a strong market sentiment and investor interest in the IPO, making it a highly anticipated event in the financial markets.
Concord Biotech IPO Subscription Status
| Day / Date | QIB | NII | RII | Emp | Total Subscription |
| 1st Day – 4th Aug | 0.01x | 1.01x | 0.73x | 5.85x | 0.59x |
| 2nd Day – 7th Aug | 1.61x | 5.22x | 2.27x | 15.90x | 2.72x |
| 3rd Day – 8th Aug | 67.67x | 16.99x | 3.78x | 24.48x | 24.87x |
| Shares Offered or Net Issue | 4,183,130 | 3,137,348 | 7,320,479 | 10,000 | 14,650,957 |
As of now, the Concord Biotech IPO Subscription status remains undisclosed. Investors eagerly await the subscription numbers and oversubscription levels, crucial indicators of market sentiment and confidence in the company’s prospects.
Official announcements and financial news platforms will provide updates once details become available. Potential investors should exercise caution and conduct thorough research before making any investment decisions, as investing in IPOs carries inherent risks.
Concord Biotech IPO Allotment Status
The Concord Biotech IPO Allotment status is not yet known as of this writing. The process of assigning shares to investors who applied for the IPO during the subscription period is referred to as allotment status.
Once the IPO subscription window has ended, the firm and the issue’s registrar carefully analyze the applications and allot shares following the IPO process’s rules and regulations.
The process of allotment entails scrutinizing bids and ensuring that shares are allocated equally among retail investors, non-institutional investors, and qualified institutional buyers following the stipulated rules.
The registrar’s website and the stock market websites where the IPO is placed are then updated with the final allotment data.
Concord Biotech IPO Live Performance
Concord Biotech’s IPO, a Book Built Issue, received strong investor interest during the August 2023 subscription period. Listed on BSE and NSE, the IPO offered shares in the price range of Rs 705 to Rs 741 per share with a total issue size of 20,925,652 shares (Rs 1,551.00 Cr).
The company’s live performance post-listing has been impressive, reflecting positive investor sentiment. Concord Biotech’s innovative biopharmaceutical products and market potential have attracted significant attention, leading to a positive stock trend.
However, investors should exercise caution, considering market fluctuations, and check out Concord Biotech IPO live performance advice before making investment decisions.
Subscribe to Concord Biotech IPO – Open Free Demat Account Now!
Latest Concord Biotech IPO News
Currently, there is not much latest Concord Biotech IPO News available regarding the Concord Biotech IPO at this time. As of now, specific updates or recent developments related to the IPO have not been widely reported by credible news sources.
Investors and market participants are eagerly awaiting further announcements and disclosures from Concord Biotech and regulatory authorities to gain insights into the latest developments surrounding the IPO.
The lack of substantial information in the news highlights the need for interested parties to keep a close eye on official announcements and updates from Concord Biotech and regulatory bodies to stay informed about any significant developments regarding the IPO.
Concord Biotech – Company Review
Concord Biotech Limited, incorporated in 1984, is an R&D-driven biopharmaceutical company based in India. It has gained recognition as one of the leading global developers and manufacturers of fermentation-based Active Pharmaceutical Ingredients (APIs) in the areas of immunosuppressants and oncology, as per market share volume data in 2022.
With a strong global presence, the company exports its products to over 70 countries, including the USA, Europe, Japan, and India.
Concord Biotech’s core offerings encompass a range of therapeutic areas, including immunosuppressants used in organ transplant and autoimmune disorder treatment, anti-infectives addressing infections, oncology drugs for cancer treatment, and nephrology drugs for kidney conditions.
The company takes pride in its successful and sustainable establishment and scaling up of fermentation-based API manufacturing capabilities.
However, this achievement comes with complexities, such as working with microbial strains, controlling multiple processes, and investing substantial capital due to barriers to entry in the fermentation-based API space..
Products or Services
Concord Biotech Limited offers a diverse range of products and services, focusing on Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, as well as finished formulations. The company’s product portfolio includes:
- Active Pharmaceutical Ingredients (APIs):
Concord Biotech specializes in the production of fermentation-based APIs, serving various therapeutic areas:
- Immunosuppressants: The company manufactures APIs used to suppress the immune system, making them crucial for patients undergoing organ transplants to prevent organ rejection. They are also employed in treating autoimmune disorders.
- Anti-bacterial: Concord Biotech offers APIs for anti-bacterial medications that are used to prevent or treat bacterial infections.
- Oncology: The company provides APIs used in the treatment of cancer, making them an essential component of cancer therapies.
- Anti-fungal: Concord Biotech’s anti-fungal APIs are utilized to prevent or treat fungal infections in patients.
- Formulations:
Thus, Concord Biotech manufactures formulations used in various therapeutic areas:
- Immunosuppressants: The company’s formulations include drugs used for immunosuppression in patients undergoing organ transplants or suffering from autoimmune disorders.
- Nephrology Drugs: Concord Biotech offers formulations designed for kidney-related conditions and treatments.
- Anti-infective Drugs: The company provides formulations for treating critical infections and ensuring patient care.
- Research and Development (R&D) Services:
Concord Biotech is an R&D-driven company with a strong focus on innovation and product development. It invests in cutting-edge research and development to create novel APIs and formulations, expanding its product portfolio and catering to emerging healthcare needs.
Promoters and Holding
Sudhir Vaid and Ankur Vaid are the promoters of Concord Biotech. They possess 30,756,044 Equity Shares in total, accounting for 29.40% of the company’s issued, subscribed, and paid-up Equity Share capital.
The Promoters have no stake in any property that the firm has bought or may acquire.
Furthermore, no payments have been made or agreed upon to persuade them to serve as directors or promoters, nor have any payments been made or agreed upon for services given by them or their related firms/companies in connection with the company’s promotion or establishment.
Is Concord Biotech Good for Investment?
Concord Biotech is well-position in India’s rapidly expanding domestic healthcare sector, which expects to increase at a CAGR of 8% to 10% from 2023 to 2026.
The company contributes significantly to this thriving industry by focusing on the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations for various therapeutic segments such as immunosuppressants, oncology, anti-bacterial, and antifungals.
India has emerged as a critical provider of generic pharmaceuticals and vaccines globally, accounting for almost 40% of total generic medication demand in the United States and around 25% of total drug demand in the United Kingdom.
The success of the country in the pharmaceutical business links to modern formulation production skills, conformity with global standards, and strong government backing.
Concord Biotech is one of the companies with the highest number of FDA-approved plants for manufacturing APIs, accounting for 28% of the share in 2022, almost twice that of the United States and China.
Moreover, the company has been actively participating in government initiatives, which aim to boost domestic manufacturing of identified KSMs, drug intermediates, and APIs and reduce India’s import dependence on critical APIs.
This scheme expects to attract significant investments and promote the production of crucial drugs for various medical conditions.
As a result, the future looks promising for Concord Biotech IPO, given India’s growing healthcare market, supportive government policies, and initiatives to enhance domestic manufacturing capabilities.
The company’s strategic positioning in the pharmaceutical sector makes it well-prepared to capitalize on emerging opportunities and contribute to the industry’s growth.
Concord Biotech Financial Statements
| Amount (in INR & Million) | |||
| 31-Mar-23 | Mar-22 | 31-Mar-21 | |
| Assets | 15,139.84 | 13,127.95 | 11,825.46 |
| Revenue |
8,884.77
|
7,363.49
|
6,307.50
|
| Expense |
5,684.24
|
4,951.93
|
3,175.81
|
| Profit After Tax |
2,400.84
|
1,749.29
|
2,348.87
|
Concord Biotech’s financial performance has shown consistent growth. As of March 31, 2023, the company’s total assets reached Rs 15,139.84 million, a significant increase from the previous year. Revenue from operations for the year ending March 31, 2023, was Rs 8,531.68 million, demonstrating steady growth.
The company’s total income reached Rs 8,884.77 million, indicating a positive trend in its financial performance.
Effective expense management and balanced financial structure contributed to the company’s profit before tax and share of profit from the joint venture, amounting to Rs 3,200.53 million. The restated profit for the period after tax was Rs 2,400.84 million, a substantial improvement from the preceding year.
The total comprehensive income for the year, attributable to the company’s owners, stood at Rs 2,403.41 million, showcasing a favorable financial position. The restated earnings per share (EPS) for the year were Rs 22.95, reflecting the company’s profitability and strong performance.
Concord Biotech’s consistent growth and solid financial indicators position. It well to leverage India’s thriving healthcare market and create value for its shareholders.
| Earnings per Equity Share (in Million) | |||
| 31-Mar-23 | Mar-22 | 31-Mar-21 | |
| Basic & Diluted |
22.95
|
16.72
|
22.45
|
Concord Biotech IPO Review
The Concord Biotech IPO offers a compelling investment opportunity in India’s thriving biopharmaceutical sector. With a strong market position and diverse product offerings, the company is a leading global developer and manufacturer of fermentation-based APIs in immunosuppressants and oncology.
Its steady financial performance, revenue of Rs 8,531.68 million, and profit before tax of Rs 3,200.53 million showcase profitability.
The IPO, with an issue size of Rs 1,551.00 Crores and a price range of Rs 705 to Rs 741 per share, lists on BSE and NSE. Amid India’s growing domestic healthcare market, the IPO presents an attractive option for investors seeking exposure to this promising industry.
Concord Biotech IPO Details
Here are a few more details you need to know before investing in Concord Biotech IPO –
Concord Biotech IPO Issue Object
Thus, Concord Biotech has proposed diverse objectives for making the IPO offer and some of the objectives are:
- To achieve the benefits of listing Equity Shares on the Stock Exchanges; and
- To carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.
Concord Biotech IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Established presence across the complex fermentation value chain;
- Global leadership in immunosuppressant APIs along with a wide spectrum of complex fermentation-based APIs across multiple therapeutic areas;
- Scaled manufacturing facilities with a consistent regulatory compliance track record supported by strong R&D capabilities;
- Diversified global customer base with long-standing relationships with key customers;
- Experienced Promoters, management team supported by marquee investors;
- Financial track record of rapid growth and consistent profitability with healthy cash flows and shareholder returns
Quantitative factors are:
| Basic & Diluted EPS | RONW (%) | NAV (Rs.) | |
| 31-Mar-23 | 22.95 | 20.06% | 123.31 |
| 31-Mar-22 |
16.72
|
16.64% | – |
| Mar-21 |
22.45
|
26.55% | – |
Concord Biotech IPO Lead Managers
Here is the list of Lead managers –
-
Kotak Mahindra Capital Company Limited
-
Citigroup Global Markets India Private Limited
-
Jefferies India Private Limited
Concord Biotech IPO Registrar to offer
Check out the details of the registrar here –
Link Intime India Private Limited
C 101, 247 Park L.B.S Marg Vikhroli (West),
Mumbai 400 083Maharashtra,
IndiaTel: +91 810 811 4949
E-mail: concordbiotech.ipo@linkintime.co.in
Website: www.linkintime.co.in
Investor Grievance ID:concordbiotech.ipo@linkintime.co.in
Contact Person: Shanti Gopalkrishnan
SEBI Registration Number: INR000004058
Concord Biotech IPO – Other Details
- Statutory Auditor – Deloitte Haskins & Sells
- Legal Counsel to the Company – Cyril Amarchand Mangaldas
- Bankers to the Company – State Bank of India and Axis Bank Limited
Concord Biotech IPO Verdict by Stock Brokers
The Concord Biotech IPO is a promising investment opportunity in the biopharmaceutical sector of India. As a leading biotechnology company, Concord Biotech has a strong market position, innovative products, and financial performance.
The IPO offers investors a chance to participate in the growth potential of the pharmaceutical industry. However, like any investment, it comes with risks, and careful evaluation is crucial.
The IPO has garnered significant interest in the grey market, indicating a positive market. Overall, the Concord Biotech IPO allows investors to be part of a company poised for success in India’s healthcare market.
Concord Biotech IPO – Conclusion
In conclusion, the Concord Biotech IPO presents a promising opportunity in India’s biopharmaceutical sector. The company’s leading position, innovative products, and strong financial performance make it an attractive investment choice.
However, investors should conduct thorough evaluations and consider the risks before participating. The IPO has garnered significant interest in the grey market, indicating positive market sentiment.
Overall, the Concord Biotech IPO offers a chance to be part of a successful company in India’s growing healthcare market. But cautious decision-making is essential.
To Subscribe to Concord Biotech IPO – Open Demat Account Now!
Concord Biotech IPO Review FAQs
Check out the FAQs on Concord Biotech IPO –
What is the Issue Size of Concord Biotech IPO?
The Company is making an initial public offer of 20,925,652 equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.
What is the Price band of Concord Biotech IPO?
The price band for this particular IPO ranges between Rs 705 to Rs 741. As far as the face value of the share is of concern, it is Rs.1 per share.
What is the Concord Biotech IPO Open Date?
The opening and closing dates for this IPO have been updated. The IPO is set to open on 4 August 2023, while the closing date is set at 8 August 2023.
What is the Concord Biotech IPO Allotment Date?
They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on 11 August 2023, refund initiation is on 14 August 2023, credit of shares is on 17 August 2023, and share listing date is on 18 August 2023.
What is the Concord Biotech IPO Listing Date?
Shares of this company shall be listed in the exchanges on 18 August 2023. The date, when the listing would be done, is stagnant on 18 August 2023.
Who is the Registrar of Concord Biotech IPO?
One of the reputed registrars is managing the issue of this IPO, i.e. Link Intime India Private Ltd. Their website will help you regarding the further information you are on the lookout for.
Who is the Promoter of Concord Biotech IPO?
Here are the promoters of this IPO – SUDHIR VAID AND ANKUR VAID. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
What is the GMP of Concord Biotech IPO?
They have obtained the GMP of this IPO and it is Rs. NA. Further insights into the Kostak rate and subject to sauda or SS are as well included in this report.
Is Concord Biotech IPO Good for Investment?
They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
What is the PAT of Concord Biotech Company?
They have the information on company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2023 in Million is 2,400.84, 2022 is 1,749.29, 2021 is 2,348.87.
Featured Topics